GlassScriptPhysician profile
Lori A Cupp
NPI 1427498682
$5,748.38
in general payments reported to CMS, 2019-2025
43 companies · $749 in 2025
The $749 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,074 · 2022: $1,496 · 2023: $773 · 2024: $657 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,093 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,093.47 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.81 | 2021-2025 | |
| Novo Nordisk INC | $471.62 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $409.59 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $389.57 | 2021-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $353.96 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $267.52 | 2022-2025 | Caplyta |
| Amgen INC. | $242.86 | 2021-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $237.55 | 2022-2025 | Rexulti, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.05 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Axsome Therapeutics, INC. | $210.55 | 2022-2025 | Auvelity, Sunosi |
| Kowa Pharmaceuticals America, INC. | $187.58 | 2021-2023 | Seglentis |
| Pfizer INC. | $180.06 | 2022-2025 | |
| Astellas Pharma US INC | $178.35 | 2021-2024 | Veozah |
| Lilly USA, LLC | $176.78 | 2021-2025 | Reyvow, Emgality, Zepbound |
| Lundbeck LLC | $161.06 | 2022-2025 | Rexulti |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $134.91 | 2021-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $134.34 | 2021 | |
| Grifols USA, LLC | $100.58 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $95.46 | 2021-2022 | |
| Electromed, INC. | $86.46 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $80.96 | 2021 | |
| Dexcom, INC. | $79.57 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $79.26 | 2021-2022 | |
| Mylan Specialty L.P. | $67.05 | 2021-2024 | Yupelri |
| Abbott Laboratories | $61.17 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $61.09 | 2021-2022 | |
| Eisai INC. | $52.40 | 2021 | |
| Nestle Healthcare Nutrition INC. | $46.18 | 2022 | |
| Alnylam Pharmaceuticals INC. | $45.29 | 2021-2024 | Givlaari |
| Xeris Pharmaceuticals, INC. | $43.81 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $41.19 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $39.96 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $39.27 | 2022 | |
| Antares Pharma, INC. | $32.14 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Boston Scientific Corporation | $31.09 | 2023 | |
| Phathom Pharmaceuticals, INC. | $30.79 | 2024-2025 | Voquezna |
| Viatris Specialty LLC | $28.91 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $28.45 | 2021-2023 | Austedo |
| Exact Sciences Corporation | $28.15 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $26.35 | 2021-2022 | |
| Radius Health, INC. | $20.18 | 2024 | Tymlos |
| Paratek Pharmaceuticals, INC. | $16.81 | 2025 | Nuzyra |
| Genentech USA, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Cupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.